JAWS Great White Staple System (includes 12, 15, 18, 20 and 25 mm staples)
ENGLEWOOD, Colo., November 14, 2023–(BUSINESS WIRE)–Paragon 28, Inc. (NYSE: FNA) is pleased to announce the launch of its JAWS™ Great White Staple System, which is designed to provide greater strength and stability to the osteotomy or fusion site compared to traditional stapling systems. The staples feature an ultra-low profile bridge with a larger surface area to improve stability and minimize soft tissue irritation. The newly designed staple has a 400 times longer fatigue life compared to a competitive nitinol staple subjected to the same loading parameters.1 The shoulders of the staple work together with the inserter, allowing the staple to fully seat before compression is activated, limiting the need for tamping. The staples are designed to provide a uniform compression profile across the entire osteotomy and provide a 169% higher compressive force compared to the average of a competitive marketing-leading two-pin nitinol staple.1
Paragon 28 CEO Albert DaCosta said: “We are excited to further expand our JAWS™ base offering, allowing surgeons to address the complexities of midfoot and hindfoot reconstruction. Our development team has designed implants that provide greater fatigue resistance and increased compression compared to leading nitinol stacking systems. We look forward to expanding our market position in the midfoot and rearfoot segments with this exciting offering.”
The addition of the JAWS™ Great White Staple System strengthens Paragon 28’s product offering of rearfoot solutions, including the Gorilla® Ankle Fracture Plating System, APEX 3D™ Total Ankle Replacement, Silverback™ Ankle Fusion Plating System, Phantom® TTC Nail System and Phantom ® ActivCore™ nail system. With this extensive portfolio, Paragon 28® offers its customers innovative ankle solutions for trauma, arthritis and limb rescue.
About Paragon 28, Inc.
Based in Englewood, CO., Paragon 28 is a leading medical device company focused exclusively on the foot and ankle orthopedic market and committed to improving the lives of patients. Since its inception, Paragon 28® has provided innovative orthopedic solutions, procedural approaches and devices covering a wide range of foot and ankle conditions, including fracture fixation, forefoot, ankle, progressive collapsing foot deformity (PCFD) or flat foot, Charcot foot and orthobiological agents . The company designs products with both the patient and surgeon in mind, with the goals of improving outcomes, reducing recurrences of disease and complications, and making procedures simpler, more consistent and reproducible.
Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to to: Paragon 28’s potential to shape a better future for foot and ankle patients. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on our current expectations, estimates and assumptions, which speak only as of the date on which they are made, and are subject to risks and uncertainties, some of which we are not currently aware of. Forward-looking statements should not be read as a guarantee of future performance or results and may not necessarily be accurate indications of the times at or at which such performance or results will be achieved. These forward-looking statements are based on Paragon 28’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements due to these risks and uncertainties. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as the risks associated with Paragon 28’s business generally, see the current and future reports from Paragon 28 filed with the Securities and Exchange Commission. Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and its Quarterly Reports on Form 10-Q, as updated periodically with its other filings with the SEC. These forward-looking statements are made as of the date of this press release, and Paragon 28 assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements . except as required by law.
Disclaimer
Nothing in this material is intended to provide specific medical advice or take the place of written law or regulation.
1. Internal test data saved
Contact person for investors
Matthew Brinckman
Senior Vice President, Strategy and Investor Relations
Phone: (720) 912-1332
mbrinckman@paragon28.com
Photo: Business Wire
https://youtu.be/YRrppL1WuCw Introduction As a weight lifter, you're no stranger to pushing your body to its…
Ever wondered why some hikers seem to move easily on tough trails while others find…
Are you an active person dealing with knee pain that stops you from doing what…
Ever wondered why your knees ache after a long ride? Cycling is great for your…
Are you an athlete struggling with knee pain that's slowing you down? You might be…
As a runner, there's nothing quite like the exhilaration of hitting the pavement, feeling the…